MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s00280-026-04896-8

Медицинская библиотека · Cancer chemotherapy and pharmacology · 2026

Targeting the GSK-3β/mTOR axis to overcome chemoresistance in gestational choriocarcinoma: molecular mechanisms and therapeutic opportunities.

Al-Hajeili Marwan, Al-Kuraishy Hayder M, Abdelaziz Ahmed M, El-Saber Batiha Gaber

СтатьяОбзорПеревод в очереди

Аннотация

Gestational choriocarcinoma represents one of the most curable solid tumors when diagnosed early, with cure rates exceeding 95% using standard chemotherapy. However, a subset of patients develops chemoresistance, leading to treatment failure and poor outcomes. Emerging evidence indicates that aberrant activation of the glycogen synthase kinase-3β (GSK-3β)/mechanistic target of rapamycin (mTOR) signaling axis is strongly associated with chemoresistance through multiple interconnected mechanisms. This review examines the molecular pathways by which GSK-3β and mTOR likely contribute to chemoresistance in gestational choriocarcinoma, including enhanced epithelial-mesenchymal transition (EMT), metabolic reprogramming, immune evasion, autophagy dysregulation, and suppression of apoptosis. We analyze how crosstalk between GSK-3β and mTOR complexes (mTORC1/mTORC2) creates a resistant phenotype that limits the efficacy of conventional cytotoxic agents such as methotrexate, actinomycin D, and etoposide. Importantly, we highlight emerging therapeutic strategies to target this axis, including GSK-3β activators (lithium, 9-ING-41), mTOR inhibitors (rapamycin analogs, dual PI3K/mTOR inhibitors), and combination regimens that synergistically restore chemosensitivity. Preclinical data from trophoblastic and related malignancies demonstrate that dual targeting of GSK-3β and mTOR can reverse resistance phenotypes and enhance treatment responses. This comprehensive review provides a translational framework for developing molecularly targeted therapies in chemoresistant gestational choriocarcinoma, with potential implications for personalized treatment algorithms and clinical trial design in this rare but highly treatable malignancy.

Для цитирования: Al-Hajeili Marwan, Al-Kuraishy Hayder M, Abdelaziz Ahmed M, El-Saber Batiha Gaber. Targeting the GSK-3β/mTOR axis to overcome chemoresistance in gestational choriocarcinoma: molecular mechanisms and therapeutic opportunities.. Cancer chemotherapy and pharmacology. 2026. DOI: 10.1007/s00280-026-04896-8.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.